How to Submit a Public Comment on Peptides Before the July 9 FDA Deadline

Seven Peptides. One Deadline. Your Window to Be Heard.

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will meet to evaluate seven peptides for inclusion on the 503A Bulks List — the list that determines which peptides compounding pharmacies can legally prepare for patients. The seven peptides under review are:

• BPC-157 — tissue repair, gut healing, injury recovery
• TB-500 (Thymosin Beta-4 Fragment) — wound healing, muscle recovery
• KPV — anti-inflammatory, gut mucosal repair
• MOTS-C — metabolic function, mitochondrial health
• Semax — neuroprotection, cognitive function
• Epitalon — telomere regulation, longevity research
• Emideltide — immune modulation

Before the committee meets, the FDA is accepting public comments through July 9, 2026. This is your legal right — and it matters. FDA advisory committee members read submitted comments. Patient and clinician perspectives have influenced PCAC recommendations before. No competitor publication has published a practical guide to submitting your comment. WellSourced is doing it now, while it still counts.

What Is Being Decided — Category 1 vs. Current Status

To understand why submitting a comment matters, you need to know what the PCAC is actually deciding.

These seven peptides currently exist in a legal gray zone. Following the April 2026 reclassification that removed them from Category 2 (the list of compounds too risky for compounding), they are no longer explicitly banned — but they also are not on the 503A Bulks List. Without a Bulks List entry, compounding pharmacies lack clear authority to prepare and dispense these peptides for individual patients.

The PCAC job is to advise the FDA on which compounds belong on the Bulks List. Category 1 recommendation = appropriate for compounding. That is the outcome that restores legal patient access through compounding pharmacies. A negative recommendation, or a recommendation for further study, extends the ambiguity indefinitely.

For deeper context on the regulatory timeline, read our FDA Peptide Reclassification guide and the full PCAC July 2026 hearing breakdown.

Why Public Comments Actually Matter

This is not a petition that gets filed away. Comments submitted to a federal docket are part of the official record. The FDA and the advisory committee review them before and during the meeting. Recurring themes across comments can surface in committee discussion.

What carries weight:

• Patient experience narratives — first-person accounts of therapeutic benefit, especially where conventional options failed
• Clinician perspectives — physicians and practitioners describing patient outcomes have significant standing
• Safety observations — real-world accounts of tolerability and lack of adverse effects from supervised use
• Access concerns — cost, availability, and the gap created for patients who cannot access FDA-approved alternatives

What does not help: generic enthusiasm, unsubstantiated health claims, or off-topic content. Comments should be substantive, specific, and ideally tied to one or more of the seven peptides under review.

Step-by-Step: How to Submit Your Comment

Step 1 — Go to regulations.gov

Open regulations.gov in your browser. This is the official federal docket portal. All public comments on FDA proceedings are submitted here.

Step 2 — Find docket FDA-2025-N-6895

In the search bar, enter the docket number exactly: FDA-2025-N-6895

This is the docket for the PCAC meeting covering the 503A Bulks List nominations including these seven peptides. You can also search for PCAC or pharmacy compounding advisory committee 2026 to locate it.

Step 3 — Click Comment Now

On the docket page, find the green Comment Now button. Click it to open the comment submission form. You do not need to create an account to submit a comment, though creating one lets you track your submission after it is filed.

Step 4 — Write your comment

Fill in your comment in the text field. You can also attach a document (PDF or Word) if you prefer to write a longer submission.

The form asks for your name and city/state. Anonymous comments are accepted but named comments carry more weight — especially from patients and clinicians.

Step 5 — Preview and submit

Use the preview option to review your comment before final submission. Once submitted, comments are publicly posted on the docket — do not include any information you do not want to be publicly visible. No medical record numbers, no full addresses.

Submit at least 48–72 hours before the July 9 deadline. The system handles high traffic near deadlines poorly and submissions can fail.

What to Include: Template and Talking Points

You do not need to write a legal brief. A focused two-to-four paragraph comment addressing your personal experience or clinical perspective is appropriate. Here is a framework:

Tips for stronger comments:

• Name the specific peptide(s) you are commenting on — do not write generically about peptides
• Ground it in a real use case: injury recovery, gut issues, neurological symptoms, metabolic health
• If you are a clinician, note your specialty and practice setting
• Keep it under 500 words unless you have substantive clinical data to include
• Avoid unsubstantiated disease cure claims — describe observed outcomes, not cures

What Happens After the Deadline

The July 9 deadline closes the comment window. After that, submitted comments are compiled and made available to PCAC members ahead of the July 23–24 meeting.

At the meeting, committee members will discuss each of the seven peptides, consider the public record (including submitted comments), review available evidence, and vote on whether each compound should be placed on the 503A Bulks List. The PCAC vote is advisory — the FDA is not required to follow it, but the agency historically tracks closely with committee recommendations.

After the PCAC vote, the formal rulemaking process begins. Realistically, expect six to eighteen months between a favorable PCAC recommendation and a finalized Bulks List update. The comment period you are participating in now is the earliest possible public input into that timeline.

If the PCAC recommends against any of these compounds, the FDA can still accept them via a separate citizen petition process — but that route is longer and less reliable than a clean PCAC approval.

The Peptides at Stake — A Quick Reference

For readers less familiar with these compounds, here is the clinical rationale that patients and clinicians typically cite:

• BPC-157 — Body Protective Compound-157. Decades of animal research showing accelerated tendon, ligament, and gut tissue repair. Widely used under physician supervision for sports injuries and IBD-type conditions.
• TB-500 — Thymosin Beta-4 synthetic fragment. Used in post-injury recovery protocols for soft tissue and muscle repair. Strong safety profile in supervised human use.
• KPV — Tripeptide with anti-inflammatory properties. Used for gut mucosal healing, particularly in patients with Crohn disease or ulcerative colitis who have failed conventional options.
• MOTS-C — Mitochondria-derived peptide. Early clinical interest for metabolic syndrome and insulin sensitivity; longevity research pipeline.
• Semax — Neuroprotective peptide with decades of clinical use in Russia and Eastern Europe. Used for cognitive function, stroke recovery, and ADHD symptom management.
• Epitalon — Tetrapeptide studied for telomere regulation and longevity effects. Used in anti-aging protocols under physician supervision.
• Emideltide — Delta sleep-inducing peptide derivative. Used for sleep quality and immune modulation.

For a broader view of where these and other peptides rank by evidence and safety, see the 2026 Peptide Tier List. For guidance on sourcing while the regulatory picture resolves, see the Peptide Supplier Buyer Guide 2026.

The Bottom Line

The FDA public comment system exists precisely for moments like this. Seven peptides that thousands of patients and practitioners depend on are up for a decision that will determine whether compounding access is restored or stays in limbo. The window closes July 9. The process takes five minutes.

Submit before the deadline. Name the compounds you care about. Write from personal experience or clinical practice. The record you help build is the one the committee reads on July 23.